EYLEA (aflibercept injection): Approved by the U.S. Food and Drug Administration (FDA) in November 2011 [REF].
PRALUENT (Alirocumab) indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein (LDL) cholesterol.